Click on image to view larger version.
Fig. 5. Mean (±SE) percent 4-day cumulative excretion of Zn65 in urine in five patients with pancreatic insufficiency (hollow bar) and five alcoholic control subjects (solid bar) during four sequential periods (I, II, III and IV) after administration of radioactive zinc (Zn65). Urinary excretion of Zn65 was significantly (p<0.05) higher in pancreatic disease patients as compared to the control subjects during the first and second 4-day period after oral administration of radioactive zinc.
